Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Adalimumab in RA Subjects Unable to Obtain Etanercept
NCT00049751Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by Abbott Laboratories. Primary endpoints: Disease Activity Score at 12 weeks and Serious Adverse Events. Started Sep 2002; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00049751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049751.